This phase II trial studies how well pembrolizumab and ibrutinib work in treating patients
with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as
pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ibrutinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma.